(VIANEWS) – CEGEDIM (CGM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CEGEDIM (CGM.PA) | €19.34 | 2.6% | 5.08% |
| TUBIZE-FIN (TUB.BR) | €70.90 | 1.18% | 4.93% |
| BIOMERIEUX (BIM.PA) | €94.76 | 0.88% | 12.95% |
| SARTORIUS STED BIO (DIM.PA) | €245.40 | 0.59% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CEGEDIM (CGM.PA)
2.6% Forward Dividend Yield and 5.08% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.01.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 19.15. Meaning, the purchaser of the share is investing €19.15 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Volatility
CEGEDIM’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.25%, a negative 0.13%, and a positive 1.26%.
CEGEDIM’s highest amplitude of average volatility was 0.45% (last week), 0.93% (last month), and 1.26% (last quarter).
Moving Average
CEGEDIM’s value is above its 50-day moving average of €18.79 and way higher than its 200-day moving average of €17.24.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CEGEDIM’s stock is considered to be oversold (<=20).
More news about CEGEDIM.
2. TUBIZE-FIN (TUB.BR)
1.18% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.91.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 37.12. Meaning, the purchaser of the share is investing €37.12 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €70.90 at 12:30 EST, way under its 52-week high of €83.70 and above its 52-week low of €65.40.
More news about TUBIZE-FIN.
3. BIOMERIEUX (BIM.PA)
0.88% Forward Dividend Yield and 12.95% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.82.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 24.81. Meaning, the purchaser of the share is investing €24.81 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.95%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 3.59B for the twelve trailing months.
Yearly Top and Bottom Value
BIOMERIEUX’s stock is valued at €94.76 at 12:30 EST, way below its 52-week high of €109.20 and way above its 52-week low of €77.48.
More news about BIOMERIEUX.
4. SARTORIUS STED BIO (DIM.PA)
0.59% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €9.63.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 25.48. Meaning, the purchaser of the share is investing €25.48 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.8%, now sitting on 3.36B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SARTORIUS STED BIO’s EBITDA is 106.08.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SARTORIUS STED BIO’s stock is considered to be oversold (<=20).
More news about SARTORIUS STED BIO.
